InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
ImPoster Free
11/08/13 1:04 PM
profile icon
ImPoster Free
07/23/13 2:30 PM
profile icon
ImPoster Free
07/09/13 9:39 AM
profile icon
ImPoster Free
05/07/07 11:50 PM
profile icon
ImPoster Free
05/07/07 11:35 PM
profile icon
ImPoster Free
05/28/06 4:18 AM
profile icon
ImPoster Free
05/28/06 2:20 AM
profile icon
ImPoster Free
02/20/06 11:52 AM
profile icon
ImPoster Free
02/19/06 10:09 PM
profile icon
ImPoster Free
02/19/06 10:07 PM
profile icon
ImPoster Free
02/19/06 9:51 PM
profile icon
ImPoster Free
02/19/06 9:50 PM
profile icon
ImPoster Free
02/19/06 9:24 PM
profile icon
ImPoster Free
02/19/06 2:37 PM
profile icon
ImPoster Free
02/19/06 2:27 PM
profile icon
ImPoster Free
02/19/06 2:26 PM
profile icon
ImPoster Free
02/19/06 2:06 PM
profile icon
ImPoster Free
02/19/06 1:47 PM
profile icon
ImPoster Free
02/19/06 1:38 PM

ImpediMed RSS Feed

Followers
2
Posters
1
Posts (Today)
0
Posts (Total)
19
Created
02/19/06
Type
Free
Moderator ImPoster
Assistants

 
 
 
IMPEDIMED HOMEPAGE
                                                                          http://impedimed.com.au/ ;                                                                             

ImpediMed is an Australian based company using bioimpedance technology in various clinical and nonclinical applications.  The clinical applications are focused primarily on lymphedema and to a far lesser extent on body composition assessment.  The nonclinical applciatiosn reside on the Xitron Technologies side of ImpediMed's business which manufactures devices for power testing and measurment.  ImpediMed is listed on the Australian Stock Exchange and trade under the ticker IPD.

The company's bioimpedance spectroscopy (BIS) technology platform provides a next generation means of accurately assessing patient-specific parameters such as fluid levels.  Earlier  generations of impedance devices (bioimpedance analysis or BIA) depended on prediction equations or algorithms to estimate these parameters based on a regression analysis of the impedance result compared to a reference method in a  specific study population.  The company holds numerous patents around the use of bioimpedance spectroscopy and its medical applications.

If there is a home run in the company's product line, it lies in the assessment of lymphedema with its L-Dex (lymphedema index) devices.  Most lymphedema (secondary as opposed to primary lymphedema) is cause by injury or insult to the body's lymphatic system induced by surgery or radiation during cancer treatment.  Lymph nodes play an integral role in the transport of lymph, a protein rich extracellular fluid, throughout the body.  Surgical removal or irradiation of these nodes during treatment can result in decreased transport capacity and hence, the accumulation of lymph in the arm, leg, trunk, or head and neck. In breast cancer patients, lymphedema of the arm is a common side effect that can occur after lymph nodes closest to the tumor are removed or irradiated during treatment.  This can result in the accumuation of lymph in the limb (arms in breast cancer patients and in the legs in gynecologic cancers) which will clinically manifest itself as swelling of the limb as lymphedema progresses.  ImpediMed's L-Dex devices compare the amount of extracellular fluid (ECF) in the patients normal or unaffected limb with the amount of ECF in the patients at-risk limb.  This ratio or index is presented to the physician and patient as an L-Dex value.  Nearly all healthy patients will have L-Dex values between -10 and +10 with 0 being the mean and +/- 10 representing 3 SD's (standard deviations) either side of the mean (0).  In statistics and many medical applications, a change or a result 2 or 3 SD's outside of the mean or a baseline value is considered significant.  In a breast cancer patient, an increase of 10 L-Dex units would indicate an accumulation of ECF in her at-risk arm although swelling may not yet be apparent.   Identificaion of early stage lymphedema allows treatment with inexpensive, off-the-shelf compression which can help prevent progression and often return women to their presurgical baselines.

In February of 2013, the company announced a co-marketing deal with 3M for the Australia/New Zealand markets.  This would link 3M new therapeutic COBAN 2 Layer Compression Therapy for lymphedema patients with a diagnostic/monitoring device (L-Dex).  If successful, it would seem reasonable that the relationship with 3M could expand to new markets, particularly in Europe.  A natural consequence of success could also be in 3M's taking greater interest in the company.  (
http://www.proactiveinvestors.com.au/companies/news/39551/impedimed-signs-multi-year-agency-deal-with-3m-for-lymphoedema-products-39551.html  )

The company has had numerous rounds of funding and has begun to cut significantly back on the cash burn rate.   Their two biggest hurdles to wide spread adoption in the US are related:  the L-Dex devices need to move from Category 3 CPT status (which is often considered experimental or investigational) to Category 1 CPT status.  The AMA is responsible for this code change determination.  The second hurdle often but not necessarily tied to this is coverage and payment by health insurance providers.  Health insurance providers such as Aetna, United Healthcare and the various Blue Cross Blue Shield plans can reimburse physicains for the use of Category 3 codes but often do not.  They are more likely to pay a Category 1 code although Category 1 status is not a guarantee of coverage or payment except by Medicare.


ImpediMed markets its medical devices primarily in Australia and the United States where regulatory clearance by the TGA and FDA, respectively, are required.   L-Dex devices are CE marked for Europe.  The L-Dex products have not been cleared by Health Canada for commercialization there.

CHART
http://au.finance.yahoo.com/charts?s=IPD.AX#symbol=ipd.ax;range=3m;compare=;indicator=sma(50,200)+volume+rsi+macd;charttype=area;crosshair=on;ohlcvalues=1;logscale=off;source=undefined;





ImpediMed Limited
Global Headquarters
Unit 1, 50 Parker Court                                       
Pinkenba, Qld 4008 Australia
Phone +61 (7) 3860-3700
Fax  +61 (7) 3260-1225

ImpediMed Incorporated
5959 Cornerstone Court West
San Diego, CA 92121
Phone: +1 (858) 412 0200
Fax: +1 (858) 558 8540

Websites: 
United States of America:  http://www.impedimed.com
Australia / International:    http://www.impedimed.com.au 

Ticker Symbol: IPD
Exchange: ASX 
Board Info
Posts Today
0
Posts (Total)
19
Posters
1
Moderator
Assistants
New Post